Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients

Hsien Yuan Lane, Oliver Yoa Pu Hu, Michael W. Jann, Hwei Chuang Deng, Hsin Nan Lin, Wen Ho Chang

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

This study examined the relationship between the metabolic ratios of dextromethorphan/dextrorphan, haloperidol disposition, and the incidence of extrapyramidal side effects in schizophrenic patients. Eighteen schizophrenic patients were phenotyped with a test dose of dextromethorphan prior to the initiation of haloperidol treatment. The metabolic ratio of dextromethorphan/dextrorphan was determined in each patient. Patients were treated with oral haloperidol 10 mg/day for 2 weeks. Blood samples for haloperidol and reduced haloperidol were obtained at week 2 of haloperidol treatment. Haloperidol and reduced haloperidol plasma concentrations were assayed by HPLC with electrochemical detection. Significant correlations of dextromethorphan/dextrorphan metabolic ratios vs, plasma haloperidol concentrations, reduced haloperidol concentrations, and reduced haloperidol/haloperidol ratios were found (r = 0.726, P = 0.0007; r = 0.782, P = 0.0001; and r = 0.619, P = 0.006, respectively). Ten patients who experienced extrapyramidal side effects had higher reduced haloperidol concentrations and reduced haloperidol/haloperidol ratios than the other patients (2.49 ± 1.42 [S.D.] ng/ml vs. 1.10 ± 0.46 ng/ml, P = 0.014 and 0.287 ± 0.102 vs. 0.192 ± 0.065, P = 0.030). The former also had a trend to have higher haloperidol concentrations and dextromethorphan/dextrorphan ratios than the latter (8.04 ± 2.91 ng/ml vs. 5.83 ± 1.79 ng/ml, P = 0.066 and 0.023 ± 0.017 vs. 0.011 ± 0.010, P = 0.077). Phenotyping patients has the potential to assist clinicians in predicting plasma drug concentrations during the subsequent neuroleptic drug treatment. Further research with phenotyping and psychotropic drug metabolism in psychiatric patients is needed.

Original languageEnglish
Pages (from-to)105-111
Number of pages7
JournalPsychiatry Research
Volume69
Issue number2-3
DOIs
Publication statusPublished - Mar 24 1997
Externally publishedYes

Fingerprint

Dextromethorphan
Haloperidol
Dextrorphan
Psychotropic Drugs
Antipsychotic Agents
Psychiatry
4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol
Therapeutics
High Pressure Liquid Chromatography

Keywords

  • Dextromethorphan
  • Extrapyramidal side effects
  • Reduced haloperidol
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Lane, H. Y., Hu, O. Y. P., Jann, M. W., Deng, H. C., Lin, H. N., & Chang, W. H. (1997). Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. Psychiatry Research, 69(2-3), 105-111. https://doi.org/10.1016/S0165-1781(96)02999-X

Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. / Lane, Hsien Yuan; Hu, Oliver Yoa Pu; Jann, Michael W.; Deng, Hwei Chuang; Lin, Hsin Nan; Chang, Wen Ho.

In: Psychiatry Research, Vol. 69, No. 2-3, 24.03.1997, p. 105-111.

Research output: Contribution to journalArticle

Lane, HY, Hu, OYP, Jann, MW, Deng, HC, Lin, HN & Chang, WH 1997, 'Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients', Psychiatry Research, vol. 69, no. 2-3, pp. 105-111. https://doi.org/10.1016/S0165-1781(96)02999-X
Lane, Hsien Yuan ; Hu, Oliver Yoa Pu ; Jann, Michael W. ; Deng, Hwei Chuang ; Lin, Hsin Nan ; Chang, Wen Ho. / Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. In: Psychiatry Research. 1997 ; Vol. 69, No. 2-3. pp. 105-111.
@article{33ef7ebee7764cb39390a4dfb8acffac,
title = "Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients",
abstract = "This study examined the relationship between the metabolic ratios of dextromethorphan/dextrorphan, haloperidol disposition, and the incidence of extrapyramidal side effects in schizophrenic patients. Eighteen schizophrenic patients were phenotyped with a test dose of dextromethorphan prior to the initiation of haloperidol treatment. The metabolic ratio of dextromethorphan/dextrorphan was determined in each patient. Patients were treated with oral haloperidol 10 mg/day for 2 weeks. Blood samples for haloperidol and reduced haloperidol were obtained at week 2 of haloperidol treatment. Haloperidol and reduced haloperidol plasma concentrations were assayed by HPLC with electrochemical detection. Significant correlations of dextromethorphan/dextrorphan metabolic ratios vs, plasma haloperidol concentrations, reduced haloperidol concentrations, and reduced haloperidol/haloperidol ratios were found (r = 0.726, P = 0.0007; r = 0.782, P = 0.0001; and r = 0.619, P = 0.006, respectively). Ten patients who experienced extrapyramidal side effects had higher reduced haloperidol concentrations and reduced haloperidol/haloperidol ratios than the other patients (2.49 ± 1.42 [S.D.] ng/ml vs. 1.10 ± 0.46 ng/ml, P = 0.014 and 0.287 ± 0.102 vs. 0.192 ± 0.065, P = 0.030). The former also had a trend to have higher haloperidol concentrations and dextromethorphan/dextrorphan ratios than the latter (8.04 ± 2.91 ng/ml vs. 5.83 ± 1.79 ng/ml, P = 0.066 and 0.023 ± 0.017 vs. 0.011 ± 0.010, P = 0.077). Phenotyping patients has the potential to assist clinicians in predicting plasma drug concentrations during the subsequent neuroleptic drug treatment. Further research with phenotyping and psychotropic drug metabolism in psychiatric patients is needed.",
keywords = "Dextromethorphan, Extrapyramidal side effects, Reduced haloperidol, Schizophrenia",
author = "Lane, {Hsien Yuan} and Hu, {Oliver Yoa Pu} and Jann, {Michael W.} and Deng, {Hwei Chuang} and Lin, {Hsin Nan} and Chang, {Wen Ho}",
year = "1997",
month = "3",
day = "24",
doi = "10.1016/S0165-1781(96)02999-X",
language = "English",
volume = "69",
pages = "105--111",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "2-3",

}

TY - JOUR

T1 - Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients

AU - Lane, Hsien Yuan

AU - Hu, Oliver Yoa Pu

AU - Jann, Michael W.

AU - Deng, Hwei Chuang

AU - Lin, Hsin Nan

AU - Chang, Wen Ho

PY - 1997/3/24

Y1 - 1997/3/24

N2 - This study examined the relationship between the metabolic ratios of dextromethorphan/dextrorphan, haloperidol disposition, and the incidence of extrapyramidal side effects in schizophrenic patients. Eighteen schizophrenic patients were phenotyped with a test dose of dextromethorphan prior to the initiation of haloperidol treatment. The metabolic ratio of dextromethorphan/dextrorphan was determined in each patient. Patients were treated with oral haloperidol 10 mg/day for 2 weeks. Blood samples for haloperidol and reduced haloperidol were obtained at week 2 of haloperidol treatment. Haloperidol and reduced haloperidol plasma concentrations were assayed by HPLC with electrochemical detection. Significant correlations of dextromethorphan/dextrorphan metabolic ratios vs, plasma haloperidol concentrations, reduced haloperidol concentrations, and reduced haloperidol/haloperidol ratios were found (r = 0.726, P = 0.0007; r = 0.782, P = 0.0001; and r = 0.619, P = 0.006, respectively). Ten patients who experienced extrapyramidal side effects had higher reduced haloperidol concentrations and reduced haloperidol/haloperidol ratios than the other patients (2.49 ± 1.42 [S.D.] ng/ml vs. 1.10 ± 0.46 ng/ml, P = 0.014 and 0.287 ± 0.102 vs. 0.192 ± 0.065, P = 0.030). The former also had a trend to have higher haloperidol concentrations and dextromethorphan/dextrorphan ratios than the latter (8.04 ± 2.91 ng/ml vs. 5.83 ± 1.79 ng/ml, P = 0.066 and 0.023 ± 0.017 vs. 0.011 ± 0.010, P = 0.077). Phenotyping patients has the potential to assist clinicians in predicting plasma drug concentrations during the subsequent neuroleptic drug treatment. Further research with phenotyping and psychotropic drug metabolism in psychiatric patients is needed.

AB - This study examined the relationship between the metabolic ratios of dextromethorphan/dextrorphan, haloperidol disposition, and the incidence of extrapyramidal side effects in schizophrenic patients. Eighteen schizophrenic patients were phenotyped with a test dose of dextromethorphan prior to the initiation of haloperidol treatment. The metabolic ratio of dextromethorphan/dextrorphan was determined in each patient. Patients were treated with oral haloperidol 10 mg/day for 2 weeks. Blood samples for haloperidol and reduced haloperidol were obtained at week 2 of haloperidol treatment. Haloperidol and reduced haloperidol plasma concentrations were assayed by HPLC with electrochemical detection. Significant correlations of dextromethorphan/dextrorphan metabolic ratios vs, plasma haloperidol concentrations, reduced haloperidol concentrations, and reduced haloperidol/haloperidol ratios were found (r = 0.726, P = 0.0007; r = 0.782, P = 0.0001; and r = 0.619, P = 0.006, respectively). Ten patients who experienced extrapyramidal side effects had higher reduced haloperidol concentrations and reduced haloperidol/haloperidol ratios than the other patients (2.49 ± 1.42 [S.D.] ng/ml vs. 1.10 ± 0.46 ng/ml, P = 0.014 and 0.287 ± 0.102 vs. 0.192 ± 0.065, P = 0.030). The former also had a trend to have higher haloperidol concentrations and dextromethorphan/dextrorphan ratios than the latter (8.04 ± 2.91 ng/ml vs. 5.83 ± 1.79 ng/ml, P = 0.066 and 0.023 ± 0.017 vs. 0.011 ± 0.010, P = 0.077). Phenotyping patients has the potential to assist clinicians in predicting plasma drug concentrations during the subsequent neuroleptic drug treatment. Further research with phenotyping and psychotropic drug metabolism in psychiatric patients is needed.

KW - Dextromethorphan

KW - Extrapyramidal side effects

KW - Reduced haloperidol

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0030903753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030903753&partnerID=8YFLogxK

U2 - 10.1016/S0165-1781(96)02999-X

DO - 10.1016/S0165-1781(96)02999-X

M3 - Article

VL - 69

SP - 105

EP - 111

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 2-3

ER -